{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Diabetic+Retinopathy",
    "query": {
      "condition": "Severe Diabetic Retinopathy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Diabetic+Retinopathy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T02:47:52.378Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06321302",
      "title": "A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "BI 764524",
          "type": "DRUG"
        },
        {
          "name": "Sham comparator to BI 764524",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept (Eylea®) - US only",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2024-05-15",
      "completion_date": "2027-08-20",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06321302"
    },
    {
      "nct_id": "NCT01805297",
      "title": "Aflibercept Injection for Proliferative Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vitreous Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection",
          "type": "DRUG"
        },
        {
          "name": "Standard Vitrectomy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2013-03",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2023-12-27",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01805297"
    },
    {
      "nct_id": "NCT04692688",
      "title": "Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy",
        "Diabetic Macular Edema",
        "NPDR - Non Proliferative Diabetic Retinopathy",
        "PDR - Proliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "APX3330",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocuphire Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2021-04-08",
      "completion_date": "2023-01-25",
      "has_results": true,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04692688"
    },
    {
      "nct_id": "NCT00198510",
      "title": "Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vitreous Hemorrhage",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Vitrase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 750,
      "start_date": "1998-11",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2013-03-15",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 61,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Chula Vista, California + 51 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00198510"
    },
    {
      "nct_id": "NCT03197870",
      "title": "The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonproliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "AKB-9778",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 167,
      "start_date": "2017-06-09",
      "completion_date": "2019-02-09",
      "has_results": true,
      "last_update_posted_date": "2023-06-27",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 53,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03197870"
    },
    {
      "nct_id": "NCT05695417",
      "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-proliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "OTX-TKI",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2023-01-15",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-12-08",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Augusta, Georgia + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Lemont",
          "state": "Illinois"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05695417"
    },
    {
      "nct_id": "NCT00130845",
      "title": "Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Octreotide Acetate in Microspheres",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 312,
      "start_date": "2000-02",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2011-11-17",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00130845"
    },
    {
      "nct_id": "NCT01270542",
      "title": "Avastin for PDR (Proliferative Diabetic Retinopathy)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinal Detachment",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Avastin (bevacizumab)",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-06",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01270542"
    },
    {
      "nct_id": "NCT04702048",
      "title": "Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Retinopathy, Diabetic"
      ],
      "interventions": [
        {
          "name": "Aflibercept Injection",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-02-01",
      "completion_date": "2024-02-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04702048"
    },
    {
      "nct_id": "NCT01790945",
      "title": "Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mild Nonproliferative Diabetic Retinopathy",
        "Moderate Nonproliferative Diabetic Retinopathy",
        "Severe Nonproliferative Diabetic Retinopathy",
        "Proliferative Diabetic Retinopathy",
        "Diabetic Macular Edema"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Retina Institute of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2013-02",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2013-02-13",
      "last_synced_at": "2026-09-27T02:47:52.378Z",
      "location_count": 1,
      "location_summary": "Hilo, Hawaii",
      "locations": [
        {
          "city": "Hilo",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01790945"
    }
  ]
}